硼替佐米联合环磷酰胺及地塞米松治疗多发性骨髓瘤的临床疗效和毒副反应

doi:10.3969/j.issn.1006-6233.2020.04.003

Abstract
Figure/Table
References
Related Citation (9)

Download: PDF (1176 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical efficacy and side effects of bortezomib combined with cyclophosphamide and dexamethasone in the treatment of multiple myeloma (MM). Methods: 70 cases of patients with multiple myeloma from October 2016 to October 2019 were divided into two groups according to the treatment, Bortezomib plus cyclophosphamide and dexamethasone group (cyclophosphamide group, n = 35) and bortezomib plus thalidomide and dexamethasone group (thalidomide group, n = 35). The clinical efficacy and toxicity of the two groups were statistically analyzed. Results: The deep response rate of cyclophosphamide group was 82.9% (29 / 35) significantly higher than that of thalidomide group 51.4% (18 / 35) (P<0.05). The incidence of side effects was 54.3% (19 / 35) in the cyclophosphamide group and 60.0%(21/35) in the thalidomide group. The difference between the two groups was not significant (P>0.05). Conclusion: The therapeutic effect of bortezomib combined with cyclophosphamide and dexamethasone is better than bortezomib combined with thalidomide and dexamethasone, and it will not increase the side effects of patients.

Key words： Bortezomib Cyclophosphamide Dexamethasone Multiple myeloma

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LU Jun
	ZHU Xijun

Cite this article:

LU Jun,ZHU Xijun. Efficacy and Side Effects of Bortezomib Combined with Cyclophosphamide and Dexamethasone in the Treatment of Multiple Myeloma[J]. HeBei Med, 2020, 26(4): 537-540.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.04.003 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I4/537